Genoway Stock

Genoway OCF Margin

The Operating Cash Flow Margin of Genoway (ALGEN.PA) as of Sep 6, 2026 is -6.80 %. In the previous year, Operating Cash Flow Margin was 24.40 % — a change of -127.89% (lower).

OCF Margin

-6.80 %

YoY

-127.89%

Last updated:

Operating Cash Flow Margin of Genoway is 2026 -6.80 % . Operating Cash Flow Margin of Genoway was 2025 24.40 % . It decreases by -127.89% lower compared to the previous year.

The Genoway OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
5.66 EUR
Jan 1, 2019
8.27 EUR
Jan 1, 2020
-1.49 EUR
Jan 1, 2021
-4.00 EUR
Jan 1, 2022
13.81 EUR
Jan 1, 2023
15.28 EUR
Jan 1, 2024
24.40 EUR
Jan 1, 2025
-6.80 EUR
The Genoway OCF Margin history
YEAROCF MarginYoY
-6.80 %-127.89%
24.40 %+59.66%
15.28 %+10.65%
13.81 %-444.93%
-4.00 %+168.42%
-1.49 %-118.05%
8.27 %+45.93%
5.66 %+20.09%
4.72 %-160.35%
-7.82 %-193.04%
8.40 %+304.07%
2.08 %
Access this data via the Eulerpool API

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genoway stock

Operating Cash Flow Margin of Genoway is -6.80 % in 2026.

Operating Cash Flow Margin of Genoway changed from 24.40 % to -6.80 %, representing a -127.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Genoway since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Genoway with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Genoway

All Key Metrics — Genoway